Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Third Quarter 2012 Financial Results

      - Company reports strong third quarter sales growth; expects to meet 2012 guidance, including EBITDA growth of 15% to 23% -

      - Company to host conference call at 4:45 p.m. ET on November 5, 2012 -


      News provided by

      Cambrex Corporation

      Nov 05, 2012, 04:07 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Nov. 5, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2012.

      Third Quarter 2012 Highlights

      • Reported sales increased by 2.8%, and excluding the impact of foreign currency, sales increased 6.9% compared to the same period last year. 
      • EBITDA decreased 13.6% to $9.6 million, compared to $11.1 million in the same period last year. 
      • Debt, net of cash was $34.5 million at the end of the quarter, an improvement of $23.7 million during the quarter which included $11.0 million of advances related to a recently announced new supply agreement, and a positive $1.0 million currency impact on foreign cash balances.

      "We had a strong quarter as sales increased across virtually all of our product categories, with record quarterly cash flow, and excellent working capital results," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex. "During the quarter, we were pleased to announce a significant new agreement to supply an active pharmaceutical ingredient for a customer's Phase 3 program, which is expected to contribute more than $20 million in sales in 2013 and potentially more in 2014. We continue to see positive industry trends, remain confident in our full year 2012 sales and profit guidance and believe we are well positioned for continued growth in 2013 and beyond."

      Third Quarter 2012 Operating Results – Continuing Operations

      Sales of $59.8 million were 2.8% higher compared to the same period last year, despite the unfavorable impact of foreign exchange of 4.1%.  This increase was primarily due to higher custom development revenues and higher volumes of generic active pharmaceutical ingredients partially offset by lower pricing.

      Gross margins increased to 31.0% from 30.6% in the same period last year, despite the unfavorable impact of foreign exchange of 2.0%.  This increase is due to favorable product mix and lower production costs partially offset by lower pricing. 

      Selling, general and administrative expenses were $11.9 million compared to $9.8 million in the same period last year.  The increase was primarily the result of higher expenses related to performance-based stock compensation, which increased as a result of the Company's recent performance compared to its peer group and the Company's higher share price, and accruals for higher annual incentive awards partially offset by favorable foreign exchange.

      Operating profit was $4.3 million compared to $5.4 million in the same period last year.  The unfavorable impact of foreign exchange, lower pricing and higher operating expenses more than offset the favorable impact of higher sales volumes.  EBITDA was $9.6 million, compared to $11.1 million in the same period last year. 

      Net interest expense was flat at $0.6 million for both the third quarters of 2012 and 2011. Higher interest rates were offset by lower average debt.  The average interest rate on debt was 2.3% compared to 1.5% in the same period last year. 

      Equity in losses of partially-owned affiliates was $0.6 million compared to $0.5 million in the same period last year, for the Company's share of losses in Zenara Pharma (Zenara), a pharmaceutical company focused on the formulation of finished dosage form products.  Cambrex owns a 51% stake in Zenara.  The Company's share of Zenara's losses includes $0.2 million and $0.3 million of non-cash amortization expense in the third quarters of 2012 and 2011, respectively.

      The provision for income taxes totaled $1.0 million and resulted in an effective tax rate of 32.5% in the quarter, which was higher compared to the same period last year due to an increase in tax reserves partially offset by an increase in profitability in the U.S. where the Company is able to utilize tax attributes to offset domestic tax expense.

      Income from continuing operations for the third quarter of 2012 was $2.0 million or $0.07 per share compared to $3.1 million or $0.10 per share in the same period last year.

      Capital expenditures and depreciation were both $5.3 million compared to $4.7 million and $5.7 million in the same period last year, respectively.

      Guidance – Continuing Operations

      The Company is reaffirming its sales and EBITDA guidance for 2012. It continues to expect that full year 2012 sales, excluding the impact of foreign currency, will increase between 10% and 13% over 2011, and that full year 2012 EBITDA will be between $54 and $58 million, an increase of 15% to 23% over 2011.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The Company is also reaffirming its guidance regarding depreciation expense, which it expects to be between $21 and $23 million in 2012.

      This financial guidance does not reflect the company's stake in Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results.  Cambrex's income statement reflects 51% of Zenara's net results within Equity in Losses of Partially-Owned Affiliates.  For 2012, the Company continues to expect Zenara to have revenues in the low single digit millions and a small EBITDA loss.

      The Company is decreasing its guidance for its full year 2012 capital expenditures to between $27 and $30 million, as certain expenditures in connection with a capital expansion project to support a new customer's Phase 3 product candidate and other important growth initiatives are now expected to occur in early 2013. 

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's third quarter 2012 Form 10-Q is filed with the SEC.

      Conference Call and Webcast

      A conference call to discuss the Company's third quarter 2012 results will begin at 4:45 p.m. Eastern Time on Monday, November 5, 2012 and last approximately 45 minutes.  Those wishing to participate should call 1-888-430-8705 for domestic and +719-325-2455 for international.  Please use the pass code 1704787 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Monday, November 12, 2012 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 1704787 to access the replay. 

      Forward Looking Statements

      This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Guidance – Continuing Operations," including the Company's expectation that full year 2012 sales, excluding the impact of foreign currency, will increase between 10% and 13% versus 2011, that our new supply agreement will contribute $20 million in 2013 and potentially more in 2014, that full year 2012 EBITDA will be between $54 and $58 million, that Zenara will have revenues in the low single digit millions and a small EBITDA loss, that capital expenditures will be approximately $27 to $30 million and that depreciation will be $21 to $23 million in 2012.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2011, captioned "Risk Factors," or otherwise described in the Company's filings with the Securities and Exchange Commission, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2011, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, governmental legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products, as well as risks relating to the Company's new supply agreement including that the Company will expend significant resources to expand its manufacturing facilities without any assurance that the new agreement will generate any revenue beyond revenue that would be earned under termination provisions within the agreement, that the customer's product candidate will be successful in Phase 3 trials or obtain the necessary regulatory approvals to commercialize the product candidate, that the customer's Phase 3 program will not be terminated early, that anticipated quantities will not be meaningfully reduced, that the planned Phase 3 and pre-launch activities will proceed on the timeline anticipated, if at all, that the Company's expansion will proceed on the anticipated timeline without disruption to existing customers or our new customer and without disruption to the Company's and its customers' ability to meet key product delivery milestones.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2011, including the Forward-Looking Statement sections therein, and other filings with the U.S. Securities and Exchange Commission.  We caution investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.

      Use of Non-GAAP Financial Measures

      EBITDA is a non-GAAP financial measure, which the Company defines as operating profit plus depreciation and amortization expense.  Other companies may have a different definition of EBITDA and, therefore, EBITDA may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA as one of several metrics to assess and analyze its operational results and trends.  Cambrex also believes it is useful to investors because it is a common operating performance metric as well as a metric routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation from U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      About Cambrex

      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   










      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended September 30, 2012 and 2011

      (in thousands, except per-share data)












      2012


      2011





      % of




      % of



      Amount


      Sales


      Amount


      Sales










      Gross Sales

      $

      59,841



      $

      58,203



          Commissions, Allowances and Rebates


      456




      412



      Net Sales


      59,385




      57,791



          Other


      (175)




      1,364



      Net Revenues


      59,210




      59,155



          Cost of Goods Sold


      40,679


      68.0%


      41,326


      71.0%










      Gross Profit


      18,531


      31.0%


      17,829


      30.6%










      Operating Expenses









          Selling, General and Administrative Expenses


      11,910


      19.9%


      9,818


      16.9%

          Research and Development Expenses


      2,347


      3.9%


      2,615


      4.5%

      Total Operating Expenses


      14,257


      23.8%


      12,433


      21.4%










      Operating Profit


      4,274


      7.1%


      5,396


      9.3%










      Other Expenses:









          Interest Expense, net


      576




      564



          Other Expenses, net


      72




      14



          Equity in Losses of Partially-Owned Affliliates


      630




      497












      Income Before Income Taxes


      2,996


      5.0%


      4,321


      7.4%










          Provision for Income Taxes


      975




      1,227












      Income from Continuing Operations

      $

      2,021


      3.4%

      $

      3,094


      5.3%










      Loss from Discontinued Operations, Net of Tax


      (332)




      (333)












      Net Income

      $

      1,689


      2.8%

      $

      2,761


      4.7%










      Basic Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.07



      $

      0.10



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)



      $

      (0.01)



         Net Income

      $

      0.06



      $

      0.09












      Diluted Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.07



      $

      0.10



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)



      $

      (0.01)



         Net Income

      $

      0.06



      $

      0.09












      Weighted Average Shares Outstanding









         Basic


      29,711




      29,483



         Diluted


      30,587




      29,528






























      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Nine Months Ended September 30, 2012 and 2011

      (in thousands, except per-share data)












      2012


      2011





      % of




      % of



      Amount


      Sales


      Amount


      Sales










      Gross Sales

      $

      207,542



      $

      187,341



          Commissions, Allowances and Rebates


      1,772




      1,226



      Net Sales


      205,770




      186,115



          Other


      801




      2,007



      Net Revenues


      206,571




      188,122



          Cost of Goods Sold


      137,167


      66.1%


      133,781


      71.4%










      Gross Profit


      69,404


      33.4%


      54,341


      29.0%










      Operating Expenses









          Selling, General and Administrative Expenses


      33,829


      16.3%


      28,097


      15.0%

          Research and Development Expenses


      7,297


      3.5%


      8,247


      4.4%

      Total Operating Expenses


      41,126


      19.8%


      36,344


      19.4%










      Operating Profit


      28,278


      13.6%


      17,997


      9.6%










      Other Expenses/(Income):









          Interest Expense, net


      1,905




      1,742



          Other Expenses/(Income), net


      96




      (271)



          Equity in Losses of Partially-Owned Affliliates


      1,221




      1,164












      Income Before Income Taxes


      25,056


      12.1%


      15,362


      8.2%










         Provision for Income Taxes


      6,069




      4,656












      Income from Continuing Operations

      $

      18,987


      9.1%

      $

      10,706


      5.7%










      Loss from Discontinued Operations, Net of Tax


      (332)




      (479)












      Net Income

      $

      18,655


      9.0%

      $

      10,227


      5.5%










      Basic Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.64



      $

      0.36



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)



      $

      (0.01)



         Net Income

      $

      0.63



      $

      0.35












      Diluted Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.63



      $

      0.36



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)



      $

      (0.01)



         Net Income

      $

      0.62



      $

      0.35












      Weighted Average Shares Outstanding









         Basic


      29,645




      29,450



         Diluted


      30,140




      29,517










      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of September 30, 2012 and December 31, 2011

      (in thousands)











      September 30,



      December 31,

      Assets



      2012



      2011








      Cash and Cash Equivalents


      $

      33,517


      $

      31,921

      Trade Receivables, net



      35,561



      36,510

      Inventories, net



      69,465



      62,095

      Prepaid Expenses and Other Current Assets



      6,666



      6,083

        Total Current Assets



      145,209



      136,609








      Property, Plant and Equipment, net



      138,794



      139,628

      Goodwill



      36,711



      36,731

      Intangible Assets, net



      4,071



      4,261

      Investments in and Advances to Partially-Owned Affliliates



      15,415



      15,090

      Other Non-Current Assets



      3,008



      3,425








        Total Assets


      $

      343,208


      $

      335,744








      Liabilities and Stockholders' Equity














      Accounts Payable


      $

      19,159


      $

      21,200

      Deferred Revenue



      11,966



      425

      Accrued Expenses and Other Current Liabilities



      44,117



      37,508

        Total Current Liabilities



      75,242



      59,133








      Long-Term Debt



      68,000



      98,000

      Deferred Income Taxes



      15,741



      16,243

      Accrued Pension Benefits



      50,613



      52,089

      Other Non-Current Liabilities



      10,345



      9,938








        Total Liabilities


      $

      219,941


      $

      235,403








        Stockholders' Equity


      $

      123,267


      $

      100,341








        Total Liabilities and Stockholders' Equity


      $

      343,208


      $

      335,744



















      CAMBREX CORPORATION


      Reconciliation of EBITDA


      For the Quarters and Nine Months Ended September 30, 2012 and 2011


      (in thousands)
















      Third Quarter 2012



      Third Quarter 2011













      Operating Profit


      $


      4,274



      $


      5,396













      Depreciation and Amortization




      5,324





      5,718













      EBITDA


      $


      9,598



      $


      11,114



























      Nine Months 2012



      Nine Months 2011













      Operating Profit


      $


      28,278



      $


      17,997













      Depreciation and Amortization




      16,134





      17,321













      EBITDA


      $


      44,412



      $


      35,318













      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.